Lys-PEG3-BA is a PROTAC degrader targeting EML4-ALK/EGFR, with DC50 values of 1.32 μM for H3122 cells (expressing EML4-ALK fusion protein) and 19.66 μM for H1975 cells (with EGFRL858R/T790M mutations). In vitro studies show that Lys-PEG3-BA can inhibit the proliferation of non-small cell lung cancer cells by modulating the ubiquitin-proteasome system. Lys-PEG3-BA is applicable for research related to non-small cell lung cancer.

Lys-PEG3-BA, at concentrations of 0-20 μM, induces the degradation of the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion protein (EML4-ALK) in H3122 (EML4-ALK) cells, achieving a degradation rate of up to 91% with an IC50 of 5.30 μM. Additionally, Lys-PEG3-BA specifically targets and degrades the mutated protein in H1975 cells harboring the EGFR L858R/T790M double mutation, with a degradation rate of 52% at 20 μM and an IC50 of 18.56 μM. Furthermore, it effectively inhibits proliferation of both H3122 and H1975 cells over 48-72 hours, with IC50 values of 5.30 μM (48 hours) and 18.56 μM (72 hours), respectively.